Trinity Biotech collabs to advance analysis on data for EpiCapture

Trinity Biotech (TRIB) announced a strategic collaboration with a leading bioinformatics company to conduct advanced analysis on clinical trial data for EpiCapture, the company’s PCR-based epigenetic liquid biopsy test for monitoring the risk of prostate cancer progressing to more aggressive forms of the disease. Offering a non-invasive method to monitor disease progression, the EpiCapture test detects DNA methylation patterns associated with high-grade prostate cancer. This collaboration will apply sophisticated bioinformatics tools to enhance the depth of analysis and support the continued development of the test.